NASDAQ$VRTX

Vertex Pharmaceuticals Incorporated · Q4 2025 earnings

Q4 2025 earnings · · After market close · Investor relations

Briefing

Vertex reported Q4 2025 total revenue of $3.19B with GAAP net income of $1.2B, or $4.65 per share.

Q4 total revenue increased 10% to $3.19 billion on continued CF performance and contributions from CASGEVY and JOURNAVX. GAAP net income was $1.2 billion ($4.65 diluted EPS); non-GAAP net income was $1.3 billion ($5.07 per share). FY25 revenue was $12.0 billion (+9%). 2026 total revenue guidance is $12.95B–$13.1B with $500M+ from non-CF products.

  • Q4 revenue $3.19B (+10% YoY).
  • GAAP net income $1.2B; non-GAAP EPS $5.07.
  • FY25 revenue $12.0B.
  • 2026 revenue guide $12.95B–$13.1B.

Headline financials

Total Revenue

$3.19B

Previous: $2.89B+10.5%
EPS (adj)

$5.07

Previous: $3.98+27.4%
Net Income

$1.19B

Previous: $913M+30.5%
Operating Income

$1.21B

Previous: $1.03B+17.5%
Gross Profit

$2.72B

Previous: $2.49B+9.5%
Total Assets

$25.6B

No prior period

Revenue & EPS history

Vertex · Revenue · Quarterly

$3.19B

Q4 2025+10.5%vs Q4 2024
Beat estimate in 9 of 15 quarters(60%)
ActualEstimate

Revenue by segment

Vertex · $2.27B total across 1 segment · Q3 2023

  • TRIKAFTA/KAFTRIO
    $2.27B+13.1%

Forward guidance

The release discusses VRTX's outlook for upcoming periods, including capital allocation, operating priorities, and market risks.

Tailwinds

  • VRTX cites operational execution and demand trends supporting the outlook.
  • Balance sheet and capital actions aim to fund growth and shareholder returns.

Headwinds

  • Macro, pricing, and input-cost volatility could pressure margins.
  • Segment mix and one-time items may affect quarter-to-quarter comparability.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q4 2025

Historical avgQ4 2025

-0.3%

Avg return

Earnings day

-0.2%

Avg return

5 days after

+1.1%

Avg return

30 days after

46%

32 / 70 earnings

Positive

+6.1%

Q3 2024

Best reaction

-9.4%

Q1 2025

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026-1.2%-0.1%+3.0%
Q4 2025+5.7%+1.1%+0.9%
Q3 2025-1.1%-3.9%+7.4%
Q2 2025+2.8%-0.1%+5.6%
Q1 2025-9.4%-15.0%-11.3%
Q4 2024-3.1%-2.3%+7.0%
Q3 2024+6.1%+9.7%-1.5%
Q2 2024+0.9%+2.4%-1.9%
Q1 2024+2.3%+5.4%+20.4%
Q4 2023-2.0%-0.4%-3.0%
Q3 2023+0.5%-0.7%-6.0%
Q2 2023-2.4%-1.6%-2.2%
Q1 2023+1.6%+2.2%-5.0%
Q4 2022-3.8%-2.5%-5.9%
Q3 2022+0.9%+1.0%+0.6%
Q2 2022+4.7%+8.7%+2.2%
Q1 2022-7.2%-12.3%-1.6%
Q4 2021+0.5%+7.0%+1.4%
Q3 2021+2.0%+4.0%+10.3%
Q2 2021-0.3%-1.1%-1.1%
Q1 2021+2.2%+0.6%-2.3%
Q4 2020-5.1%-6.0%-9.0%
Q3 2020+0.0%+1.3%+8.8%
Q2 2020-2.4%-1.1%-3.1%
Q1 2020-2.2%+3.0%+12.1%
Q4 2019-2.3%+3.1%-3.6%
Q3 2019-1.2%+0.8%+12.1%
Q2 2019+5.8%+3.6%+6.2%
Q1 2019+0.0%+0.8%-1.3%
Q4 2018-3.0%-3.5%-5.0%
Q3 2018-4.9%-2.2%-7.9%
Q2 2018+0.6%-0.3%+1.1%
Q1 2018+0.6%-1.7%+1.5%
Q4 2017+3.9%-6.8%+2.1%
Q3 2017-4.9%-1.0%-3.0%
Q2 2017-3.6%-6.3%-5.4%
Q1 2017+1.7%+1.8%+3.1%
Q4 2016+3.8%+2.6%+4.7%
Q3 2016-0.0%-1.5%+10.9%
Q2 2016+1.3%+3.4%+2.2%
Q1 2016+3.1%
Q4 2015+0.6%
Q3 2015+4.3%
Q2 2015+5.6%
Q1 2015-1.7%
Q4 2014-7.7%
Q3 2014-1.5%
Q2 2014-3.7%
Q1 2014-2.0%
Q4 2013+3.6%
Q3 2013-7.8%
Q2 2013+1.5%
Q1 2013-1.9%
Q4 2012-2.8%
Q3 2012-6.8%
Q2 2008-1.6%
Q1 2012+2.5%
Q4 2011+2.3%
Q3 2011-0.7%
Q2 2011+4.5%
Q1 2011-1.8%
Q4 2008-1.2%
Q4 2010-1.2%
Q3 2009-0.1%
Q3 2010-0.1%
Q2 2010+5.1%
Q2 2009+5.1%
Q1 2010-0.8%
Q1 2009-0.8%
Q4 2009-0.8%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro